[go: up one dir, main page]

NO20083979L - Farmasoytisk sammensetning omfattende oseltamivirfosfat - Google Patents

Farmasoytisk sammensetning omfattende oseltamivirfosfat

Info

Publication number
NO20083979L
NO20083979L NO20083979A NO20083979A NO20083979L NO 20083979 L NO20083979 L NO 20083979L NO 20083979 A NO20083979 A NO 20083979A NO 20083979 A NO20083979 A NO 20083979A NO 20083979 L NO20083979 L NO 20083979L
Authority
NO
Norway
Prior art keywords
sugar
pharmaceutical composition
oseltamivir phosphate
weight
sugar alcohol
Prior art date
Application number
NO20083979A
Other languages
English (en)
Other versions
NO342112B1 (no
Inventor
Ryuji Kubota
Tomoaki Ohta
Tomoaki Hirayama
Hiroyuki Maeda
Christian Volland
Hans-Guenter Kaestle
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38437365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083979(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20083979L publication Critical patent/NO20083979L/no
Publication of NO342112B1 publication Critical patent/NO342112B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En farmasøytisk sammensetning omfattende minst en eksipient valgt fra et sukker og en sukkeralkohol som hver har et likevekts-fuktighetsinnhold på 1 vekt% eller lavere ved 25°C og 70% relativ fuktighet og oseltamivirfosfat, hvori sukkeret eller sukkeralkoholen inneholder glukose og mannose som urenheter hver i en mengde på 0,01 vekt% eller mindre i forhold til vekten av sukkeret eller sukkeralkoholen.
NO20083979A 2006-02-20 2008-09-18 Farmasøytisk sammensetning omfattende oseltamivirfosfat og anvendelse derav NO342112B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006042178 2006-02-20
PCT/JP2007/053081 WO2007097325A1 (ja) 2006-02-20 2007-02-20 リン酸オセルタミビル含有医薬組成物

Publications (2)

Publication Number Publication Date
NO20083979L true NO20083979L (no) 2008-11-11
NO342112B1 NO342112B1 (no) 2018-03-26

Family

ID=38437365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083979A NO342112B1 (no) 2006-02-20 2008-09-18 Farmasøytisk sammensetning omfattende oseltamivirfosfat og anvendelse derav

Country Status (15)

Country Link
US (1) US9012499B2 (no)
EP (1) EP1987825B1 (no)
JP (1) JP5255429B2 (no)
KR (1) KR20080097468A (no)
CN (1) CN101389323B (no)
AU (1) AU2007218733B2 (no)
BR (1) BRPI0708108B1 (no)
CA (1) CA2642952C (no)
HK (1) HK1126971A1 (no)
IL (1) IL193372A (no)
NO (1) NO342112B1 (no)
RU (1) RU2008137613A (no)
SG (1) SG183583A1 (no)
WO (1) WO2007097325A1 (no)
ZA (1) ZA200806356B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
WO2010071232A1 (en) * 2008-12-17 2010-06-24 Sato Pharmaceutical Co., Ltd. A disintegrating tablet
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
CN102166206B (zh) * 2011-02-12 2012-10-10 李春娟 液体的磷酸奥司他韦组合物
RU2633085C2 (ru) * 2014-05-20 2017-10-11 Российская Федерация, от имени которой выступает Федеральное государственное казенное учреждение "Войсковая часть 68240" Противовирусное лекарственное средство в виде капсул и способ его получения
KR20160002177A (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 오셀타미비어 유리염기를 포함하는 약학 조성물
WO2016052945A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Granules containing oseltamivir, capsules comprising the granules, and method of preparing the capsules
WO2016088010A1 (en) * 2014-12-01 2016-06-09 Lupin Atlantis Holdings Sa Oseltamivir compositions
KR20160117070A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법
KR101953294B1 (ko) 2018-04-12 2019-03-04 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292451A (en) * 1978-03-30 1981-09-29 Ici Americas Inc. High mannitol process (alkaline hydrogenation in presence of alkali metal carbonate)
JPH0813737B2 (ja) 1986-12-19 1996-02-14 杏林製薬株式会社 シロツプ剤
JPH0723304B2 (ja) * 1988-04-19 1995-03-15 三菱化学株式会社 薬剤成分固定化組成物
JP4165878B2 (ja) * 1993-06-03 2008-10-15 株式会社林原生物化学研究所 トレハロース遊離酵素とその製造方法並びに用途
JPH0827033A (ja) * 1994-07-14 1996-01-30 Nikken Chem Co Ltd エリスリトール含有固形剤
AU720933B2 (en) 1995-02-27 2000-06-15 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases
CN1213299A (zh) * 1996-02-09 1999-04-07 剑桥夸准脱控股有限公司 包含海藻糖的固体制剂
JP3126683B2 (ja) 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
IL126580A (en) 1996-04-16 2001-08-08 Bayer Ag D- Manitol and its preparation
WO1998007685A1 (en) 1996-08-23 1998-02-26 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
JPH1135486A (ja) 1997-07-23 1999-02-09 Lion Corp 薬用固形製剤
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
JP3228335B2 (ja) 1998-02-26 2001-11-12 萬有製薬株式会社 口腔内崩壊型組成物及びその製造方法
WO1999043306A1 (en) 1998-02-26 1999-09-02 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US20040202714A1 (en) * 1999-10-12 2004-10-14 Daiichi Suntory Pharma Co., Ltd. Oral pharmaceutical composition
CN1236764C (zh) * 2000-06-27 2006-01-18 霍夫曼-拉罗奇有限公司 制备组合物的方法
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
JP5100391B2 (ja) 2005-10-05 2012-12-19 京都薬品工業株式会社 経口用組成物
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets

Also Published As

Publication number Publication date
BRPI0708108B1 (pt) 2021-12-14
US9012499B2 (en) 2015-04-21
CA2642952A1 (en) 2007-08-30
CA2642952C (en) 2014-09-02
US20100222427A1 (en) 2010-09-02
JP5255429B2 (ja) 2013-08-07
AU2007218733B2 (en) 2012-11-15
BRPI0708108A2 (pt) 2011-05-17
IL193372A0 (en) 2009-09-22
IL193372A (en) 2015-09-24
KR20080097468A (ko) 2008-11-05
WO2007097325A1 (ja) 2007-08-30
JPWO2007097325A1 (ja) 2009-07-16
CN101389323B (zh) 2013-08-21
NO342112B1 (no) 2018-03-26
EP1987825A4 (en) 2012-10-17
SG183583A1 (en) 2012-09-27
CN101389323A (zh) 2009-03-18
ZA200806356B (en) 2009-11-25
EP1987825B1 (en) 2018-09-05
EP1987825A1 (en) 2008-11-05
RU2008137613A (ru) 2010-03-27
HK1126971A1 (en) 2009-09-18
AU2007218733A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
NO20083979L (no) Farmasoytisk sammensetning omfattende oseltamivirfosfat
NO20092525L (no) Anvendelse av komposittmateriale som barriere under kryogene betingelser
NO20076283L (no) Fremgangsmate for produksjon av lavmolekylaer vektheparin
WO2009088572A3 (en) Method of treating erythropoietin hyporesponsive anemias
EP1907470A4 (en) IONIC LIQUID RECONSTITUTED CELLULOSE COMPOSITES AS SOLID CARRIER MATRICES
WO2007122581A3 (en) Compositions and kits of phenylephrine
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
WO2007113327A3 (en) Fungicide n-cyclopropyl-sulfonylamide derivatives
WO2007083193A3 (en) Methods for controlling pests using rnai
WO2009115557A3 (en) Fungicide hydroximoyl-tetrazole derivatives
DK2332947T3 (da) F a s t e f o r me r a f (2S,3R,4R,5S,6R)-2-(4-chlor-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol og fremgangsmåder til disses anvendelse
EA201391651A1 (ru) Сокристаллы l-пролина и лимонной кислоты (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфенил)тиофен-2-ил)метил)-4-метилфенил)-6-(гидроксиметил)тетрагидро-2h-пиран-3,4,5-триол
NO20076355L (no) Dengue serotype 1 attenuert stamme
FR2927335B1 (fr) Hydrolysat de proteines de poissons presentant une activite satietogene, compositions nutraceutiques et pharmacologiques comprenant un tel hydrolysat et procede d'obtention
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2009090237A3 (en) Fungicide hydroximoyl-tetrazole derivatives
BR112012013922A2 (pt) composição de grão inteiro hidrolisado
ATE423548T1 (de) Pharmazeutische zusammensetzung
BR112012012782A2 (pt) formulações aprimoradas de fosfitos
DK2277799T3 (da) Hydreret fugtighedsbekæmpelsesstof og fremgangsmåde til fremstilling deraf
BRPI0518889A2 (pt) plantas de cana-de-aÇécar com um conteédo de carboidrato de armazenamento aumentado
AR067143A1 (es) Almidones con alto contenido de amilosa y propiedades de procesamiento mejoradas
NO20090562L (no) Sammensetninger for behandling av kroniske degenerative inflammatoriske tilstander
BR112012026714A2 (pt) pastilhas de eritritol e isomalte